Dr. David Samadi is the current chairman of urology at Lenox Hill Hospital. He also serves as the Chief of robotic surgery of urology at the facility. He has been at Lenox Hill Hospital since 2013. Dr. David Samadi has worked in other facilities such as Mount Sinai Hospital as a urology department head. He is highly rated in the country due to his vast knowledge and experience in urology and prostrate cancer treatment. He is popular for the use of minimally invasive surgery to treat prostrate cancer. Dr. Samadi is also a personal doctor to many celebrities in the United States.Dr. Samadi’s journey to greatness hasn’t been a walk in the park. He was born in Iran and raised there in his early years. When he was fifteen years old, he fled to Belgium together with his brother following the revolution that engulfed Iran in 1979. Life was difficult for Dr. David Samadi and his siblings following their escape from Iran.
However, they never gave up and together they put concerted efforts to ensure that they would survive in the foreign land. Dr. Samadi had a long-held ambition of becoming a doctor. The escape from his mother country did not prevent him from pursuing the dream. Samadi and his brother later moved to the United States, and they both admit that life here was better than where they came from. After six years in the United States, Dr. Samadi completed his degree at Stony Brook School of Medicine. Dr. David Samadi has attended many other reputable institutions in the country and abroad.
After finishing his undergraduate degree in Stony Brook, he did a masters degree at the same institution. He has also attended other institutions such as Memorial Sloan-Kettering Cancer Center, Albert Einstein College of Medicine and Montefiore Medical Center. He finished studying at the Henri Mondor Hospital Creteil that is in France.Dr. David Samadi has made a name in Prostrate surgeries in his many year’s careers in the medical industry. He has performed an astonishing over 7000 surgeries. He acquired vast amounts of expertise of this exercise while working at Columbia Presbyterian Hospital. He was the Director of Robotic Laparoscopic Surgery in this facility for many years. He is an expert in the treatment of the various cancers that affect the male reproductive system. He also treats other cancerous infections such as kidney cancer and many other urological ailments. His treatment solutions are meant to offer the patient instant relief from their diseases as well as improve their sexual life.
When founding Seattle Genetics, Dr. Clay Siegall wanted to build a company that would create targeted drug therapies using antibody drug conjugates. He runs the company as its chief executive officer where he handles the strategic vision of the company, forms partnerships with other companies in the pharmaceutical industry, and oversees day to day operations.
Clay has a bachelor’s degree in zoology, acquired at The University of Maryland, and a Ph.D. in genetics that he earned at George Washington University. He was in research and development for a number of years before founding Seattle Genetics in 1998. When he started Seattle Genetics it was running with basically a skeleton crew of fellow researchers. It is now a much bigger company that employs more than 650 people. They also offer fellowships and internships to up and coming researchers, many of them students at the nearby University of Washington.
In order to research their drugs and bring them to market, Dr. Clay Siegall has formed a number of key strategic partnerships. Among these are some of the biggest corporations in the industry such as Pfizer and Bayer. His company has more than 20 drugs under development and one on the market that provides a cure for lymphoma, Adcetris.
Dr. Clay Siegall firmly believes that targeted drug therapies are much safer and more effective than conventional ways of treating cancer. Conventional methods involve surgery, chemotherapy, and radiation which are very harmful to the body. Targeted therapies, on the other hand, seek out and kill only cancerous cells. They leave normal cells completely alone. He’s excited to be playing such an important role in the advance of medicine as we’re increasingly seeing nowadays.
Seattle Genetics makes money a number of ways, Dr. Siegall says. Selling their own proprietary drugs is, of course, the key money maker. They also earn money by forming production partnerships with other firms in the industry. He licenses technology and processes they have created at Seattle Genetics to other companies. He says that creating drugs is a huge risk as only 1 in 10 drugs under development are ever approved. He has formed these partnerships in order to mitigate that.
Cancer is among diseases associated with widespread deaths around the globe. Thus, there has been an increase in the demand for information relating to its treatment and management. The information is a result of intensive researches conducted by scientists in the biomedical field. The specific branch of medicine dealing with the prevention diagnosis and treatment of cancer is known as Oncology. In the fight against cancer, it has become apparent that understanding the influence of other fields in prevention and treatment is of the essence. One journal that has significantly been involved in disseminating information relating to Oncology is Oncotarget.
Oncotarget is a multidisciplinary traditional medical journal covering all aspects of oncology. The peer-reviewed journal moved from a weekly publication to being published two times in a week owing to increased demand. The demand was attributed to its impact and quality. Also, Oncotarget’s insightful, constructive, and multi peer-review has enabled authors to publish essential research papers. The journal accepts publications from different authors which are reviewed by a highly qualified and experienced who facilitate timely publishing of the papers. In essence, it has endeavored to explore different therapies, management approaches, and their impact on patients.
The online journal operates on a free-access basis. An issue may be printed if there is a particular demand. Oncotarget has been instrumental in the increased spread of significant scientific information, in particular, in the medical field. It has provided an ample platform to foster the application of basic and clinical science in the search for preventive and curative measures to deal with cancer. The journal introduced other sections covering Cell Biology, Neuroscience, Endocrinology, and Pharmacology among others. The idea has further enhanced Oncotarget’s role through linking of different biomedical fields. The integration of this knowledge is an essential step towards the fight against cancer.
Cancer is a serious disease that ends lives much too soon all around the world. With such a terrible disease, it’s no surprise that measures are being taken to help treat it more efficiently. Many of us, especially Eric Lefkofsky, wonder how we can better diagnose cancer and find the best treatments available. According to this recent article regarding the health field and cancer itself, Eric Lefkofsky believes that critical data is missing from today’s medical research systems.
Eric Lefkofsky founder and CEO of Tempus, which is a startup that aims to provide more successful accuracy in treating cancer by supplying data for both genomics and therapeutic data. This would allow doctors to fine-tune cancer treatments and provide better overall care for their patients. With Tempus, there is a free flow of information between researchers, clinicians, and others.
After his wife was diagnosed with breast cancer, Lefkofsky felt personally inclined to start and develop Tempus. The central idea behind Tempus is to build a technology layer above existing electronic medical records and pathology systems to aggregate the data and receive an edited version back with patterns of treatments and results, showing which have been proven to successful.
In addition to Tempus, Eric Lefkofsky is known for many other notable works. He is the co-founder of Groupon, which is a global e-commerce marketplace used by many around the world. In 2006, he opened up the Lefkofsky Family Foundation, which is a private charitable foundation.
He opened this foundation up with his wife, Liz, in order to enhance the lives in the communities it serves. With Tempus just being a small glimpse of his work in the healthcare industry, Lefkofsky also serves as a Trustee of Lurie Children’s Hospital of Chicago. He also has a passion for the arts, being a Trustee at the Art Institute of Chicago and Chairman of the Board of Trustee’s of Chicago’s Steppenwolf Theatre Company.
for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/